Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Open Access
- 18 February 2014
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 160 (4) , 221-232
Abstract
The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available. To determine the most cost-effective strategy for dual antiplatelet therapy after percutaneous coronary intervention for ACS. Decision-analytic model. Published literature, Medicare claims, and life tables. Patients having percutaneous coronary intervention for ACS. Lifetime. Societal. Five strategies were examined: generic clopidogrel, prasugrel, ticagrelor, and genotyping for polymorphisms of CYP2C19 with carriers of loss-of-function alleles receiving either ticagrelor (genotyping with ticagrelor) or prasugrel (genotyping with prasugrel) and noncarriers receiving clopidogrel. Direct medical costs, quality-adjusted life years(QALYs), and incremental cost-effectiveness ratios (ICERs). The clopidogrel strategy produced$179 301 in costs and 9.428 QALYs. Genotyping with prasugrel was superior to prasugrel alone, with an ICER of $35 800 per QALY relative to clopidogrel. Genotyping with ticagrelor was more effective than genotyping with prasugrel ($30 200 per QALY relative to clopidogrel). Ticagrelor was the most effective strategy($52 600 per QALY relative to genotyping with ticagrelor). Stronger associations between genotype and thrombotic outcomes rendered ticagrelor substantially less cost-effective ($104 800 per QALY). Genotyping with prasugrel was the preferred therapy among patients who could not tolerate ticagrelor. No randomized trials have directly compared genotyping strategies or prasugrel with ticagrelor. Genotype-guided personalization may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary intervention for ACS, but ticagrelor for all patients may bean economically reasonable alternative in some settings.Keywords
This publication has 82 references indexed in Scilit:
- Cost‐Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or PrasugrelPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular EventsJAMA, 2011
- High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCIJAMA, 2011
- Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary InterventionJAMA, 2011
- Prasugrel and CancerArchives of internal medicine (1960), 2010
- Variability in Individual Responsiveness to ClopidogrelJACC, 2007
- A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAmerican Heart Journal, 2007
- Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice: Results From a Large Multicenter RegistryJACC, 2006
- The Cost of an Emergency Department Visit and Its Relationship to Emergency Department VolumeAnnals of Emergency Medicine, 2005
- Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysisThe American Journal of Medicine, 2004